| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.003 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.003 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.17 | 0.004 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |